Screening for epidermal growth factor receptor mutations in lung cancer.

By R. Rosell, T. Morán, C. Queralt, R. Porta, F. Cardenal, C. Camps, M. Majem, G. López-Vivanco, D. Isla, M. Provencio and 18 more. New England Journal of Medicine, 2009

1,067 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/aac2041662afae34b0a7f072caec5c07e078b476

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Gad Getz
2. Nathanael S. Gray
3. L. Jones

Citations in the corpus

• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation (2010, neutral): “The T790M mutation has also occasionally been detected in tumor specimens from patients with no prior exposure to EGFR TKIs (3, 16–19), though the prevalence of Authors' Affiliations: 1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, 2 Molecular Diagnostics Servi”
• Advances in understanding cancer genomes through second-generation sequencing (2010, background): “For example, treatment with the inhibitors of the epidermal growth factor receptor kinase (EGFR), gefitinib and erlotinib, leads to a significant survival benefit in patients with lung cancer whose tumours carry EGFR mutations, but no benefit in patients whose tumours carry wild-type EGFR”
• Developing irreversible inhibitors of the protein kinase cysteinome (2013, positive): “Despite lung cancer patients that express mutant EGFR (exon 19 deletion or L858R) displaying dramatic responses to firstgeneration ATP-competitive inhibitors initially, all patients relapse after 12–18months (Rosell et al., 2009).”